Kaur Eshwarya Jessy, Barmon Debabrata, Baruah Upasana, Begum Dimpy
Department of Obstetrics and Gynaecology, Command Hospital, Lucknow, Uttar Pradesh, India.
Department of Gynaecological Oncology, Dr. B Borooah Cancer Institute, Tata Memorial Hospital, Guwahati, Assam, India.
J Midlife Health. 2024 Jul-Sep;15(3):161-166. doi: 10.4103/jmh.jmh_55_24. Epub 2024 Oct 17.
The term "Multiple Primary Malignant Neoplasms (MPMNs)" refers to two or more unrelated primary malignant neoplasms that originate from single or different organs and occur in one patient. MPMNs have been divided into synchronous and metachronous based on time duration after first malignancy.
This was a hospital-based retrospective study conducted at a tertiary cancer institute in Northeast India. Clinicopathological factors of patients with multiple primary malignancies with at least one female genital tract malignancy attending the gynecological oncology outpatient department were observed. Those with ambiguous status of primary malignancy and incomplete treatment of first primary malignancy were excluded from the study.
A total of 57 patients with MPMN, including one case of triple primary malignancy, were included in the study. 59.18% of cases had metachronous, and 40.81% had synchronous malignancies. The median time to the development of second primary malignancy was 60 months. Among the first diagnosed malignancies, cervix was the most common site (26.5%), followed by endometrium (20.4%) and ovary (14.28%), whereas ovarian malignancy was more commonly diagnosed second malignancy (38.77%), followed by endometrium (14.28%) and cervix (10.2%). In an analysis of synchronous malignancies, the most common genital tract involvement was seen with endometrium and ovary, with a predominance of low-grade endometrioid histology in 75% of cases.
As the cancer survivor population continues to increase in future, these patients must be comprehensively evaluated on follow-up, and a cognizance of prior treatment taken should be kept. In addition, it is vital that the clinicians keep a lookout for high-risk population in which genetic testing may be beneficial.
“多原发性恶性肿瘤(MPMNs)”一词是指起源于单个或不同器官且发生在同一患者体内的两个或更多不相关的原发性恶性肿瘤。根据首次发生恶性肿瘤后的时间长短,MPMNs已分为同时性和异时性。
这是一项在印度东北部一家三级癌症研究所进行的基于医院的回顾性研究。观察了在妇科肿瘤门诊就诊的患有多原发性恶性肿瘤且至少有一处女性生殖道恶性肿瘤的患者的临床病理因素。原发性恶性肿瘤状态不明确以及首次原发性恶性肿瘤治疗不完整的患者被排除在研究之外。
本研究共纳入57例MPMN患者,包括1例三原发性恶性肿瘤患者。59.18%的病例为异时性恶性肿瘤,40.81%为同时性恶性肿瘤。发生第二原发性恶性肿瘤的中位时间为60个月。在首次诊断的恶性肿瘤中,宫颈是最常见的部位(26.5%),其次是子宫内膜(20.4%)和卵巢(14.28%),而卵巢恶性肿瘤是更常见的第二恶性肿瘤(38.77%),其次是子宫内膜(14.28%)和宫颈(10.2%)。在同时性恶性肿瘤的分析中,最常见的生殖道受累部位是子宫内膜和卵巢,75%的病例以低级别子宫内膜样组织学为主。
随着未来癌症幸存者群体的持续增加,这些患者在随访时必须进行全面评估,并应了解其既往治疗情况。此外,临床医生留意可能从基因检测中获益的高危人群至关重要。